DC Bead

DC Bead® is an embolic Drug-Eluting Bead capable of loading and releasing in a controlled manner chemotherapeutic agents. 

DC Bead product shot

DC Bead is used in trans-arterial chemoembolisation (TACE).  This is a minimally invasive (non-surgical) procedure performed by an interventional radiologist. 

DC Bead is produced from a biocompatible polyvinyl alcohol (PVA) hydrogel that has been modified with sulphonate groups for the controlled loading and delivery of chemotherapeutic drugs.  DC Bead occludes the blood flow to the target tissue and delivers a local and sustained dose of drug direct to the tumour.

DC Bead is tinted blue for easy visualisation and is supplied in colour coded vials for added procedural safety and efficiency.

Drug-Eluting Bead doxorubicin (DEBDOX)

DC Bead is intended to be loaded with doxorubicin for the purpose of: 

  • Embolisation of vessels supplying malignant hypervascularised tumour(s)
  • Delivery of a local, controlled, sustained dose of doxorubicin to the tumour(s)

Drug-Eluting Bead irinotecan (DEBIRI)

DC Bead in intended to be loaded with irinotecan for the purpose of:

  • Embolisation of vessels supplying malignant colorectal cancer metastasised to the liver (mCRC)
  • Capable of eluting a local, controlled, sustained dose of irinotecan to hepatic metastases of colorectal cancer

DC Bead is CE-Mark approved for loading with doxorubicin (DEBDOX) and irinotecan (DEBIRI).

View DC Bead Clinical Trial Programme

Regulatory notices and product safety data

Worldwide (excluding USA and Canada)

DC Bead® is CE marked and is indicated for the treatment of malignant hypervascular tumours and loading with doxorubicin drug. DC Bead® is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC). For full prescribing information please refer to DC Bead instructions for use.

USA

DC Bead is not currently available for sale or distribution in the USA. DC Bead has not been submitted for approval to the FDA.

Canada

DC Bead® with doxorubicin is indicated for trans-arterial chemoembolization (TACE) of unresectable hepatocellular carcinoma (HCC). DC Bead are also intended to be loaded with irinotecan for the purpose of embolization of vessels supplying malignant colorectal cancer metastasised to the liver (mCRC), and delivery of a local, controlled, sustained dose of irinotecan to the mCRC. For full prescribing information please refer to DC Bead Canada Instructions for Use 

Tawain

DC Bead is approved by the Department of Health and is intended to be loaded with Mayne (Hospira) doxorubicin HCI for the purpose of embolisation of vessels supplying malignant hypervascularised tumour(s), and delivery of a local, controlled, sustained dose of doxorubicin.  DC Bead is also indicated for the embolisation of nidus vessels without medication.  Approved size ranges in Taiwan are 300-500µm and 500-700µm.